Association of ficolin-3 with severity and outcome of chronic heart failure

PLoS One. 2013 Apr 15;8(4):e60976. doi: 10.1371/journal.pone.0060976. Print 2013.

Abstract

Background: Inflammatory mechanisms involving complement activation has been shown to take part in the pathophysiology of congestive heart failure, but the initiating mechanisms are unknown. We hypothesized that the main initiator molecules of the lectin complement pathway mannose-binding lectin (MBL), ficolin-2 and ficolin-3 were related to disease severity and outcome in chronic heart failure.

Methods and results: MBL, ficolin-2 and ficolin-3 plasma concentrations were determined in two consecutive cohorts comprising 190 patients from Hungary and 183 patients from Norway as well as controls. Disease severity and clinical parameters were determined at baseline, and all-cause mortality was registered after 5-years follow-up. In univariate analysis a low level of ficolin-3, but not that of MBL or ficolin-2, was significantly associated with advanced heart failure (New York Heart Association Class IV, p<0.001 for both cohorts) and showed inverse correlation with B- type natriuretic peptide (BNP) levels (r = -0.609, p<0.001 and r = -0.467, p<0.001, respectively). In multivariable Cox regression analysis, adjusted for age, gender and BNP, decreased plasma ficolin-3 was a significant predictor of mortality (HR 1.368, 95% CI 1.052-6.210; and HR 1.426, 95% CI 1.013-2.008, respectively). Low ficolin-3 levels were associated with increased complement activation product C3a and correspondingly decreased concentrations of complement factor C3.

Conclusions: This study provides evidence for an association of low ficolin-3 levels with advanced heart failure. Concordant results from two cohorts show that low levels of ficolin-3 are associated with advanced heart failure and outcome. The decrease of ficolin-3 was associated with increased complement activation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Chronic Disease
  • Complement Activation
  • Complement C3 / immunology
  • Complement C3 / metabolism
  • Complement Pathway, Mannose-Binding Lectin
  • Female
  • Ficolins
  • Glycoproteins / blood*
  • Heart Failure / blood*
  • Heart Failure / immunology
  • Heart Failure / mortality
  • Humans
  • Lectins / blood*
  • Male
  • Mannose-Binding Lectin / metabolism
  • Middle Aged
  • Prognosis
  • Severity of Illness Index

Substances

  • Complement C3
  • FCN3 protein, human
  • Glycoproteins
  • Lectins
  • Mannose-Binding Lectin

Grants and funding

This work was supported by the Danish Medical Research Council, The Novo Nordisk Research Foundation, The Sven Andersen Research Foundation, the Research Foundation of The Capital Region of Denmark, Rigshospitalet and The Hungarian Research Fund (NF72689), and the Hungarian Ministry of Welfare (ETT 229/2006). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.